VSIR and neoplasm: The KRASG12D peptide vaccine improved survival (HR = 0.43, 95% CI: 0.25-0.74) and reduced tumor burden, while the combination of vaccine and anti-VISTA treatment achieved optimal tumor-free survival (HR = 0.38, 95% CI: 0.22-0.66).